
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8878964/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. European Urology Oncology, 2023, 6, 228-232.	5.4	11
2	Critical analysis of quality of life and cost-effectiveness of enhanced recovery after surgery (ERAS) for patient's undergoing urologic oncology surgery: a systematic review. World Journal of Urology, 2022, 40, 1325-1342.	2.2	21
3	Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 10.e7-10.e12.	1.6	4
4	Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non–muscle-invasive Bladder Cancer. European Urology Oncology, 2022, 5, 268-272.	5.4	1
5	Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study. Cancer Biomarkers, 2022, 33, 151-157.	1.7	9
6	Role of Lymphadenectomy during Radical Cystectomy for Nonmuscle-Invasive Bladder Cancer: Results from a Multi-Institutional Experience. Journal of Urology, 2022, 207, 551-558.	0.4	7
7	Reducedâ€dose bacillus Calmetteâ€Guérin (BCC) in an era of BCG shortage: realâ€world experience from a tertiary cancer centre. BJU International, 2022, 130, 323-330.	2.5	8
8	Clinicopathological analysis and outcomes of inflammatory myofibroblastic tumours of the urinary bladder. BJU International, 2022, 130, 604-610.	2.5	3
9	Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. European Urology, 2022, 81, 316-317.	1.9	5
10	Geographic distribution of racial differences in mortality in muscle-invasive bladder cancer patients: an opportunity for improvement. Cancer Causes and Control, 2022, 33, 613-622.	1.8	4
11	Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter. Bladder Cancer, 2022, 8, 113-117.	0.4	2
12	Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 273.e1-273.e9.	1.6	3
13	Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin. European Urology Oncology, 2022, 5, 84-91.	5.4	24
14	Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. American Journal of Clinical Pathology, 2022, 158, 263-269.	0.7	7
15	Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Communications Medicine, 2022, 2, .	4.2	49
16	Management, Surveillance Patterns, and Costs Associated With Low-Grade Papillary Stage Ta Non–Muscle-Invasive Bladder Cancer Among Older Adults, 2004-2013. JAMA Network Open, 2022, 5, e223050.	5.9	23
17	Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. European Urology, 2022, 81, 223-228.	1.9	8
18	Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology—Young Academic Urologists: Urothelial Carcinoma Working Group. European Urology Focus, 2022, 8, 1635-1642.	3.1	7

#	Article	IF	CITATIONS
19	Recurrence mechanisms of non-muscle-invasive bladder cancer — a clinical perspective. Nature Reviews Urology, 2022, 19, 280-294.	3.8	48
20	Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2022, 22, 361-370.	2.4	5
21	Five and Ten-Year Outcomes of Neoadjuvant Chemotherapy and Surgery for High-Risk Upper Tract Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 176-182.	1.9	5
22	International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer. European Urology, 2022, 82, 34-46.	1.9	30
23	Contemporary Staging for Muscle-Invasive Bladder Cancer: Accuracy and Limitations. European Urology Oncology, 2022, 5, 403-411.	5.4	17
24	Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. European Urology Oncology, 2022, 5, 505-516.	5.4	18
25	Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 382.e1-382.e6.	1.6	3
26	All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. Journal of Urology, 2022, 208, 284-291.	0.4	7
27	The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with nonâ€muscleâ€invasive bladder cancer treated with bacillus Calmette–Guérin. BJU International, 2021, 128, 65-71.	2.5	13
28	Bacillus Calmette-Guérin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage. European Urology Oncology, 2021, 4, 826-828.	5.4	5
29	Bladder Cancer Guidelines: Let Not the Cure Be Worse than the Disease. European Urology, 2021, 79, 105-106.	1.9	2
30	Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. European Urology Oncology, 2021, 4, 12-19.	5.4	26
31	Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed With Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care. Urology, 2021, 147, 127-134.	1.0	2
32	Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 237.e1-237.e5.	1.6	6
33	Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncology, The, 2021, 22, 107-117.	10.7	172
34	Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guérin. European Urology, 2021, 80, 1-3.	1.9	11
35	Does Variant Histology Change Management of Non-muscle-invasive Bladder Cancer?. European Urology Oncology, 2021, 4, 510-514.	5.4	10
36	The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis. Advances in Therapy, 2021, 38, 1584-1600.	2.9	3

#	Article	IF	CITATIONS
37	Impact of upper tract urothelial carcinoma on response to BCG in patients with nonâ€muscleâ€invasive bladder cancer. BJU International, 2021, 128, 568-574.	2.5	2
38	Use of psychotropic drugs among older patients with bladder cancer in the United States. Psycho-Oncology, 2021, 30, 832-843.	2.3	1
39	Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. European Urology Oncology, 2021, , .	5.4	1
40	Data Sharing Under the General Data Protection Regulation. Hypertension, 2021, 77, 1029-1035.	2.7	47
41	The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer. European Urology, 2021, 79, 437-439.	1.9	3
42	Delayed surgery for localised and metastatic renal cell carcinoma: a systematic review and meta-analysis for the COVID-19 pandemic. World Journal of Urology, 2021, 39, 4295-4303.	2.2	9
43	Time interval from transurethral resection of bladder tumour to bacille Calmette–Guérin induction does not impact therapeutic response. BJU International, 2021, 128, 634-641.	2.5	5
44	Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. European Urology Oncology, 2021, 4, 893-903.	5.4	31
45	Revisiting an Old Conundrum: A Systematic Review and Meta-Analysis of Intravesical Therapy for Treatment of Urothelial Carcinoma of the Prostate. Bladder Cancer, 2021, 7, 243-252.	0.4	4
46	Current Therapy and Emerging Intravesical Agents to Treat Non–Muscle Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2021, 35, 513-529.	2.2	12
47	Reply by Authors. Journal of Urology, 2021, 205, 1620-1621.	0.4	0
48	Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design. Journal of Urology, 2021, 205, 1612-1621.	0.4	31
49	Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. Journal of Urology, 2021, 206, 1258-1267.	0.4	7
50	What Women Want: Radical Cystectomy and Perioperative Sexual Function Educational Needs. Urology, 2021, 157, 181-187.	1.0	8
51	Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center. World Journal of Urology, 2021, 39, 4143-4149.	2.2	5
52	100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19. Nature Reviews Urology, 2021, 18, 611-622.	3.8	80
53	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
54	B2B: Bladder Cancer Summary. Société Internationale D'urologie Journal, 2021, 2, S7-S16.	0.4	0

#	Article	IF	CITATIONS
55	Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncology, The, 2021, 22, 919-930.	10.7	239
56	Oncologic Equipoise Between Robotic and Open Radical Cystectomy. Journal of Endourology, 2021, 35, 1168-1176.	2.1	1
57	Reply by Authors. Journal of Urology, 2021, 206, 1267.	0.4	Ο
58	Performance of Narrow Band Imaging (NBI) and Photodynamic Diagnosis (PDD) Fluorescence Imaging Compared to White Light Cystoscopy (WLC) in Detecting Non-Muscle Invasive Bladder Cancer: A Systematic Review and Lesion-Level Diagnostic Meta-Analysis. Cancers, 2021, 13, 4378.	3.7	35
59	Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-GuA©rin: Implications for Clinical Trial Design. Reply Journal of Urology, 2021, , 101097JU000000000002238.	0.4	0
60	Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy. Journal of Urology, 2021, 206, 577-585.	0.4	14
61	Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nature Reviews Urology, 2021, , .	3.8	6
62	The association of Coronavirus Disease-19 mortality and prior bacille Calmette-Guerin vaccination: a robust ecological analysis using unsupervised machine learning. Scientific Reports, 2021, 11, 774.	3.3	26
63	Immunotherapy in Bacillus Calmette–Guerin (BCG) unresponsive nonmuscle invasive bladder cancer. Current Opinion in Urology, 2021, 31, 160-169.	1.8	2
64	Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. European Urology Oncology, 2021, 4, 927-942.	5.4	40
65	Should Patients With Nonâ€Muscleâ€Invasive Bladder Cancer Discontinue Fibrin Clot Inhibitors During BCC?. BJU International, 2021, , .	2.5	1
66	Cost-Effectiveness of Robot-assisted Radical Cystectomy Using a Propensity-matched Cohort. European Urology Focus, 2020, 6, 88-94.	3.1	25
67	Editorial: Basic research in bladder cancer – refining the tools. 3rd IBCN seminars series1. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 855-857.	1.6	0
68	New horizons in bladder cancer research. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 867-885.	1.6	7
69	Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails. European Urology, 2020, 77, 1-2.	1.9	3
70	What Is the Significance of Variant Histology in Urothelial Carcinoma?. European Urology Focus, 2020, 6, 653-663.	3.1	126
71	A Case for Risk-adapted Management of Low-grade Bladder Tumors. European Urology Oncology, 2020, 3, 128-129.	5.4	3
72	How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Guérin?. European Urology Oncology, 2020, 3, 252-257.	5.4	1

#	Article	IF	CITATIONS
73	Locally advanced prostate cancer imaging findings and implications for treatment from the surgical perspective. Abdominal Radiology, 2020, 45, 865-877.	2.1	2
74	Predictors of Response to Intravesical Therapy. Urologic Clinics of North America, 2020, 47, 23-33.	1.8	5
75	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effortâ€. European Urology, 2020, 77, 223-250.	1.9	132
76	Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clinical Cancer Research, 2020, 26, 882-891.	7.0	98
77	Re: Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 2020;77:420–33. European Urology, 2020, 77, e105-e106.	1.9	29
78	Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. European Urology, 2020, 78, 893-906.	1.9	112
79	Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nature Medicine, 2020, 26, 1845-1851.	30.7	193
80	Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. IScience, 2020, 23, 101201.	4.1	18
81	Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. Journal of Sexual Medicine, 2020, 17, 1995-2004.	0.6	12
82	Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. European Urology Oncology, 2020, 3, 622-630.	5.4	38
83	The role of the urologist, BCG vaccine administration, and SARS oVâ€2: An overview. BJUI Compass, 2020, 1, 87-92.	1.3	6
84	Impact of Alzheimer's disease and related dementia diagnosis following treatment for bladder cancer. Journal of Geriatric Oncology, 2020, 11, 1118-1124.	1.0	3
85	Bacillus Calmette Guérin (BCG) vaccination use in the fight against COVID-19 – what's old is new again?. Future Oncology, 2020, 16, 1323-1325.	2.4	22
86	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. European Urology, 2020, 78, 29-42.	1.9	110
87	Converging Roads to Early Bladder Cancer. European Urology, 2020, 78, 127-130.	1.9	5
88	Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. European Urology, 2020, 77, 669-670.	1.9	30
89	Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non–muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. European Urology Oncology, 2020, 3, 318-340.	5.4	26
90	KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. Future Oncology, 2020, 16, 507-516.	2.4	47

#	Article	IF	CITATIONS
91	Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non–muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. European Urology, 2020, 78, 387-399.	1.9	28
92	Impact of Diagnosing Urologists and Hospitals on the Use of Radical Cystectomy. European Urology Open Science, 2020, 19, 27-36.	0.4	1
93	Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. European Urology, 2020, 78, 719-730.	1.9	73
94	NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?. Nature Reviews Urology, 2020, 17, 491-492.	3.8	5
95	Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 247-254.	1.6	3
96	Riskâ€adapted management of lowâ€grade bladder tumours: recommendations from the International Bladder Cancer GroupÂ(IBCG). BJU International, 2020, 125, 497-505.	2.5	31
97	COVID-19 and Bacillus Calmette-Guérin: What is the Link?. European Urology Oncology, 2020, 3, 259-261.	5.4	61
98	Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. American Journal of Clinical Pathology, 2020, 154, 208-214.	0.7	3
99	Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 796.e1-796.e6.	1.6	13
100	The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. Journal of Urology, 2020, 203, 283-291.	0.4	10
101	Pembrolizumab (pembro) for the treatment of patients with Bacillus Calmette-Guérin (BCG) unresponsive, high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Over two years follow-up of KEYNOTE-057 Journal of Clinical Oncology, 2020, 38, 5041-5041.	1.6	25
102	BCG shortage: Reassessing the clinical viability of Bacillus Calmette-Guerin (BCG) after reconstitution Journal of Clinical Oncology, 2020, 38, 534-534.	1.6	1
103	Trimodal therapy in muscle invasive bladder cancer management. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2020, 72, 650-662.	3.9	8
104	Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD–SIU joint consultation on bladder cancer. World Journal of Urology, 2019, 37, 3-13.	2.2	42
105	Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 815-817.	1.6	0
106	What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. European Urology Oncology, 2019, 2, 625-642.	5.4	88
107	Discerning Patterns and Quality of Neoadjuvant Chemotherapy Use Among Patients with Muscle-invasive Bladder Cancer. European Urology Oncology, 2019, 2, 497-504.	5.4	23
108	Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncology, 2019, 5, 1790.	7.1	8

#	Article	IF	CITATIONS
109	The impact of squamous histology on survival in patients with muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 353.e17-353.e24.	1.6	32
110	Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer. JAMA Surgery, 2019, 154, e191629.	4.3	28
111	Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Reports, 2019, 27, 1781-1793.e4.	6.4	102
112	Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018. Nature Reviews Urology, 2019, 16, 377-386.	3.8	51
113	Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts. Cancers, 2019, 11, 577.	3.7	13
114	Intravesical Therapy – BCG and Beyond. Bladder Cancer, 2019, 5, 73-80.	0.4	2
115	The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World Journal of Urology, 2019, 37, 2691-2698.	2.2	10
116	Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. Future Oncology, 2019, 15, 1323-1334.	2.4	33
117	Clinical and Genomic Considerations for Variant Histology in Bladder Cancer. Current Oncology Reports, 2019, 21, 23.	4.0	16
118	Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. European Urology Oncology, 2019, 2, 119-125.	5.4	16
119	Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. European Urology Oncology, 2019, 2, 286-293.	5.4	8
120	Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. European Urology Oncology, 2019, 2, 355-364.	5.4	25
121	Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer—Reply. JAMA Surgery, 2019, 154, 186.	4.3	4
122	Hospital length of stay following radical cystectomy for muscle-invasive bladder cancer: Development and validation of a population-based prediction model. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 837-843.	1.6	9
123	Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what. World Journal of Urology, 2019, 37, 2017-2029.	2.2	33
124	Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. European Urology, 2019, 75, 8-10.	1.9	31
125	Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057 Journal of Clinical Oncology, 2019, 37, 4530-4530.	1.6	4
126	Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG) Journal of Clinical Oncology, 2019, 37, 350-350.	1.6	103

#	Article	IF	CITATIONS
127	Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review. European Urology, 2018, 73, 925-933.	1.9	209
128	Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 423-431.	1.6	16
129	Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. Cancer, 2018, 124, 3127-3135.	4.1	37
130	Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU International, 2018, 122, 89-98.	2.5	28
131	Contribution of bladder cancer pathology assessment in planning clinical trials. Urologic Oncology: Seminars and Original Investigations, 2018, 39, 713-719.	1.6	8
132	Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. Journal of Urology, 2018, 199, 1158-1165.	0.4	82
133	Secondary Tumors After Urinary Diversion. Urologic Clinics of North America, 2018, 45, 91-99.	1.8	4
134	It's all about the perspective: Removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer—A competing risks analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 39-42.	1.6	2
135	Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?. European Urology, 2018, 74, 405-408.	1.9	12
136	Editorial: Managing locally advanced bladder cancer. Third International Bladder Cancer Network seminars series. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 403-404.	1.6	1
137	Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma. Urologic Clinics of North America, 2018, 45, 155-167.	1.8	14
138	Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic TO Stage in Bladder Cancer Treated with Radical Cystectomy. European Urology Focus, 2018, 4, 720-724.	3.1	23
139	Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed With Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e99-e111.	1.9	7
140	Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. European Urology, 2018, 73, 738-748.	1.9	112
141	Effects of thiazolidinedione in patients with active bladder cancer. BJU International, 2018, 121, 244-251.	2.5	3
142	The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. European Urology, 2018, 73, 543-557.	1.9	105
143	Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 413-422.	1.6	32
144	Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non–muscle-invasive Bladder Cancer. European Urology Focus, 2018, 4, 512-521.	3.1	16

#	Article	IF	CITATIONS
145	Editorial comment. Current Opinion in Urology, 2018, 28, 555-556.	1.8	Ο
146	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. European Urology Oncology, 2018, 1, 91-100.	5.4	46
147	New Horizons in Bladder Cancer Research: Report of the 15th Meeting of the International Bladder Cancer Network (IBCN) in Lisbon, Portugal, October 21–23, 2017. Bladder Cancer, 2018, 4, 339-342.	0.4	Ο
148	Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. European Urology, 2018, 74, 784-795.	1.9	530
149	Current Use and Promise of Urinary Markers for Urothelial Cancer. Current Urology Reports, 2018, 19, 96.	2.2	19
150	Advances in risk stratification of bladder cancer to guide personalized medicine. F1000Research, 2018, 7, 1137.	1.6	34
151	Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Human Pathology, 2018, 79, 57-65.	2.0	48
152	Salvage topical therapy for upper tract urothelial carcinoma. World Journal of Urology, 2018, 36, 2027-2034.	2.2	11
153	Welcome to European Urology Oncology: Your New Journal, Where Multiple Disciplines Meet To Improve Care of Patients with Genitourinary Cancers. European Urology Oncology, 2018, 1, 1-2.	5.4	3
154	Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer. JAMA Surgery, 2018, 153, 881.	4.3	73
155	Role of Checkpoint Inhibition in Localized Bladder Cancer. European Urology Oncology, 2018, 1, 190-198.	5.4	26
156	Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. European Urology, 2018, 74, 597-608.	1.9	61
157	Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy. Clinical Genitourinary Cancer, 2018, 16, e909-e917.	1.9	18
158	Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. European Urology Oncology, 2018, 1, 223-230.	5.4	25
159	Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World Journal of Urology, 2017, 35, 337-353.	2.2	74
160	Underutilization of Radical Cystectomy Among Patients Diagnosed with Clinical Stage T2 Muscle-invasive Bladder Cancer. European Urology Focus, 2017, 3, 258-264.	3.1	51
161	BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nature Reviews Urology, 2017, 14, 244-255.	3.8	108
162	CF3DODA-Me induces apoptosis, degrades Sp1, and blocks the transformation phase of the blebbishield emergency program. Apoptosis: an International Journal on Programmed Cell Death, 2017, 22, 719-729.	4.9	17

#	Article	IF	CITATIONS
163	Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer. Cancer Causes and Control, 2017, 28, 755-766.	1.8	23
164	Solubilization and Stability of Mitomycin C Solutions Prepared for Intravesical Administration. Drugs in R and D, 2017, 17, 297-304.	2.2	13
165	Strategies to minimize readmission rates following major urologic surgery. Therapeutic Advances in Urology, 2017, 9, 111-119.	2.0	11
166	Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. Journal of Urology, 2017, 198, 552-559.	0.4	632
167	RalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbishield emergency program. Cell Death Discovery, 2017, 3, 17023.	4.7	16
168	Plasmacytoid Urothelial Carcinoma of the Urinary Bladder. American Journal of Clinical Pathology, 2017, 147, 500-506.	0.7	52
169	High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette–Guerin therapy: A long-term survival analysis. Oncolmmunology, 2017, 6, e1265719.	4.6	18
170	Should we care more about <scp>SPARE</scp> ?. BJU International, 2017, 120, 605-606.	2.5	1
171	High-grade neuroendocrine carcinoma of the urachus—report of 3 cases. Human Pathology, 2017, 67, 126-133.	2.0	2
172	Cancer and All-cause Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy: Development and Validation of a Nomogram for Treatment Decision-making. Urology, 2017, 110, 76-83.	1.0	23
173	The Blebbishield Emergency Program Overrides Chromosomal Instability and Phagocytosis Checkpoints in Cancer Stem Cells. Cancer Research, 2017, 77, 6144-6156.	0.9	13
174	Surface PD-L1,ÂE-cadherin, CD24, and VEGFR2 as markers of epithelial cancer stem cells associated with rapid tumorigenesis. Scientific Reports, 2017, 7, 9602.	3.3	47
175	Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes. Journal of Endourology, 2017, 31, 946-953.	2.1	33
176	Survival differences among patients with bladder cancer according to sex: Critical evaluation of radical cystectomy use and delay to treatment. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 602.e1-602.e9.	1.6	12
177	Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. European Urology Focus, 2017, 3, 577-583.	3.1	10
178	Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU International, 2017, 119, 684-691.	2.5	36
179	Blebbishields and mitotic cells exhibit robust macropinocytosis. BioFactors, 2017, 43, 181-186.	5.4	9
180	Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer, 2017, 3, 147-148.	0.4	2

#	Article	IF	CITATIONS
181	CDK4/6 Inhibitors in Cancer Therapy: AÂNovel Treatement Strategy for Bladder Cancer. Bladder Cancer, 2017, 3, 79-88.	0.4	21
182	Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. Bladder Cancer, 2017, 3, 145-146.	0.4	8
183	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. , 2017, 5, 68.		68
184	Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) inÂBCG-Unresponsive Patients. Bladder Cancer, 2017, 3, 65-71.	0.4	24
185	Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. Journal of Clinical Oncology, 2017, 35, 3410-3416.	1.6	124
186	Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice, 2017, 13, 621-625.	2.5	40
187	Immune response results from vesigenurtacel-I (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC) Journal of Clinical Oncology, 2017, 35, 4531-4531.	1.6	3
188	Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin. Oncotarget, 2017, 8, 88782-88791.	1.8	3
189	Bladder cancer: 2017 and beyond. Indian Journal of Urology, 2017, 33, 104.	0.6	5
190	What is new in non-muscle-invasive bladder cancer in 2016?. Turkish Journal of Urology, 2017, 43, 9-13.	1.3	32
191	The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer – A New Analysis. Bladder Cancer, 2016, 2, 273-278.	0.4	46
192	Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder Cancer, 2016, 2, 203-213.	0.4	3
193	Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Annals of Surgical Oncology, 2016, 23, 4110-4114.	1.5	22
194	Follow-up in non–muscle-invasive bladder cancer—International Bladder Cancer Network recommendations. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 460-468.	1.6	60
195	Endocytosis and serpentine filopodia drive blebbishield-mediated resurrection of apoptotic cancer stem cells. Cell Death Discovery, 2016, 2, .	4.7	24
196	Novel PKC-ζ to p47phox interaction is necessary for transformation from blebbishields. Scientific Reports, 2016, 6, 23965.	3.3	20
197	CDODA-Me decreases specificity protein transcription factors and induces apoptosis in bladder cancer cells through induction of reactive oxygen species. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 337.e11-337.e18.	1.6	18
198	Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. European Urology, 2016, 70, 778-785.	1.9	25

#	Article	IF	CITATIONS
199	Taking the next step—Advancing bladder cancer management. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 435-436.	1.6	1
200	Optimum management of nonâ€muscleâ€invasive micropapillary variant urothelial carcinoma: possibility for missed chance of cure?. BJU International, 2016, 118, 349-350.	2.5	6
201	Microhematuria assessment an IBCN consensus—Based upon a critical review of current guidelines. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 437-451.	1.6	25
202	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.	0.4	30
203	Innovation in Bladder Cancer Immunotherapy. Journal of Immunotherapy, 2016, 39, 291-297.	2.4	4
204	The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy. World Journal of Urology, 2016, 34, 1561-1566.	2.2	5
205	Bladder cancer. Lancet, The, 2016, 388, 2796-2810.	13.7	1,031
206	Novel fluorescence <i>inÂsitu</i> hybridizationâ€based definition of bacille Calmetteâ€Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies. BJU International, 2016, 117, 754-760.	2.5	35
207	Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. Journal of Clinical Oncology, 2016, 34, 1935-1944.	1.6	279
208	Smac mimetic with TNF-α targets Pim-1 isoforms and reactive oxygen species production to abrogate transformation from blebbishields. Biochemical Journal, 2016, 473, 99-107.	3.7	17
209	Re: Samantha Cambier, Richard J. Sylvester, Laurence Collette, et al. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin. Eur Urol 2016;69:60–9. European Urology, 2016, 69, e121-e122.	1.9	6
210	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Human Molecular Genetics, 2016, 25, 1203-1214.	2.9	38
211	Reply from Authors re: Tahlita C.M. Zuiverloon, Ellen C. Zwarthoff. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We Moving Forward? Eur Urol 2016;69:201–2. European Urology, 2016, 69, 203.	1.9	1
212	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naÃ-ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. European Urology, 2016, 69, 855-862.	1.9	228
213	Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 59.e1-59.e8.	1.6	51
214	Natural Compounds Targeting STAT3 Mediated Inflammation. European Urology, 2016, 69, 405-406.	1.9	2
215	Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. European Urology, 2016, 69, 197-200.	1.9	136

216 Clinical Management. , 2016, , 143-151.

#	Article	IF	CITATIONS
217	New discoveries in the molecular landscape of bladder cancer. F1000Research, 2016, 5, 2875.	1.6	5
218	Urothelial Carcinoma with Variant Histology: Sarcomatoid, Plasmacytoid, and Micropapillary. , 2016, , 95-108.		0
219	Pelvic recurrence after radical cystectomy: a call to arms. BJU International, 2015, 116, 172-173.	2.5	10
220	The Prognostic Value of Previous Irradiation on Survival of Bladder Cancer Patients. Bladder Cancer, 2015, 1, 171-179.	0.4	3
221	Clarification of Bladder Cancer Disease States Following Treatment of Patients with Intravesical BCG. Bladder Cancer, 2015, 1, 29-30.	0.4	75
222	A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion® FISH, NMP22® and cytology based on imputation of multiple datasets. BMC Medical Research Methodology, 2015, 15, 45.	3.1	24
223	Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells. Oncology Reports, 2015, 34, 2738-2744.	2.6	17
224	Clinical Outcomes of cT1 Micropapillary Bladder Cancer. Journal of Urology, 2015, 193, 1129-1134.	0.4	101
225	Re: Herr et al.: BCG-refractory vs. BCG-relapsing non–muscle-invasive bladder cancer: A prospective cohort outcomes study (Urol Oncol 2015; 33: 108.el-108.e4). Urologic Oncology: Seminars and Original Investigations, 2015, 33, 335-336.	1.6	0
226	Genetic Variants in the Wnt/β-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. Journal of Urology, 2015, 194, 1771-1776.	0.4	32
227	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 53-64.	1.6	11
228	Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nature Reviews Urology, 2015, 12, 225-235.	3.8	139
229	Mitochondrial DNA Content as Risk Factor for Bladder Cancer and Its Association with Mitochondrial DNA Polymorphisms. Cancer Prevention Research, 2015, 8, 607-613.	1.5	18
230	Nonurothelial Bladder Cancer and Rare Variant Histologies. Hematology/Oncology Clinics of North America, 2015, 29, 237-252.	2.2	68
231	Immune Therapies in Non-Muscle Invasive Bladder Cancer. Current Treatment Options in Oncology, 2015, 16, 5.	3.0	6
232	Urachal carcinoma: a pathologic and clinical study of 46 cases. Human Pathology, 2015, 46, 1808-1814.	2.0	78
233	Re: Richard J. Sylvester, Willem Oosterlinck, Sten Holmang, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation? Eur	1.9	0
234	Urol, in press. http://dx.doi.org/10.1016/j.eururo.2015.05.050. European Urology, 2015, 68, e127. Efficacy and Safety of MCNA in Patients with Nonmuscle Invasive Bladder Cancer at High Risk for Recurrence and Progression after Failed Treatment with bacillus Calmette-Guérin. Journal of Urology, 2015, 193, 1135-1143.	0.4	75

#	Article	IF	CITATIONS
235	In-vitro cytocidal effect of water on bladder cancer cells: The potential role for intraperitoneal lavage during radical cystectomy. Canadian Urological Association Journal, 2015, 9, 109.	0.6	7
236	Uroplakin II Is a More Sensitive Immunohistochemical Marker Than Uroplakin III in Urothelial Carcinoma and Its Variants. American Journal of Clinical Pathology, 2014, 142, 864-871.	0.7	41
237	Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nature Reviews Urology, 2014, 11, 589-596.	3.8	69
238	Clinical significance of ureteric †skip lesions' at the time of radical cystectomy: the <scp>M</scp> . <scp>D</scp> . <scp>A</scp> nderson experience and literature review. BJU International, 2014, 113, E28-33.	2.5	16
239	Variant histology. Current Opinion in Urology, 2014, 24, 517-523.	1.8	51
240	Clinical–Pathologic Stage Discrepancy in Bladder Cancer Patients Treated With Radical Cystectomy: Results From the National Cancer Data Base. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1048-1056.	0.8	71
241	Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. Urology, 2014, 83, 863-868.	1.0	82
242	Alvimopan Accelerates Gastrointestinal Recovery After Radical Cystectomy: A Multicenter Randomized Placebo-Controlled Trial. European Urology, 2014, 66, 265-272.	1.9	186
243	Differential expression of GATA-3 in urothelial carcinoma variants. Human Pathology, 2014, 45, 1466-1472.	2.0	51
244	Reply. Urology, 2014, 83, 1432.	1.0	0
245	Alvimopan, a Peripherally Acting μ-Opioid Receptor Antagonist, is Associated with Reduced Costs after Radical Cystectomy: Economic Analysis of a Phase 4 Randomized, Controlled Trial. Journal of Urology, 2014, 191, 1721-1727.	0.4	56
246	Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition. Journal of Urology, 2014, 191, 20-27.	0.4	98
247	Myths and Mysteries Surrounding Bacillus Calmette-Guérin Therapy for Bladder Cancer. European Urology, 2014, 65, 267-269.	1.9	36
248	Genome-wide association study identifies multiple loci associated with bladder cancer risk. Human Molecular Genetics, 2014, 23, 1387-1398.	2.9	137
249	Assessing the quality of studies on the diagnostic accuracy of tumor markers. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1051-1060.	1.6	16
250	Intravesical Tumor Involvement of the Trigone Is Associated With Nodal Metastasis in Patients Undergoing Radical Cystectomy. Urology, 2014, 84, 1147-1151.	1.0	23
251	Considerations on the use of urine markers in the management of patients with high-grade non–muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1069-1077.	1.6	34
252	Micropapillary bladder cancer: Current treatment patterns and review of the literature. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 826-832.	1.6	48

#	Article	IF	CITATIONS
253	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer, 2014, 120, 1794-1799.	4.1	154
254	Predicting Response to Bacillus Calmette-Guérin: Time to Look Beyond the Ages. European Urology, 2014, 66, 702-703.	1.9	0
255	Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non–muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1061-1068.	1.6	39
256	Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. Journal of Urology, 2014, 191, 40-47.	0.4	153
257	Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2014, 192, 305-315.	0.4	82
258	Invasive extramammary Paget's disease of the bladder diagnosed 18years after noninvasive extramammary Paget's disease of the vulva. Gynecologic Oncology Case Reports, 2014, 8, 27-29.	0.9	7
259	Anterior Fascial Fixation Does Not Reduce the Parastomal Hernia Rate After Radical Cystectomy and Ileal Conduit. Urology, 2014, 83, 1427-1432.	1.0	18
260	Bladder Cancer Stem Cells: Biological and Therapeutic Perspectives. Current Stem Cell Research and Therapy, 2014, 9, 89-101.	1.3	44
261	Lymphadenectomy with Robotic Cystectomy. Current Urology Reports, 2013, 14, 59-63.	2.2	4
262	Comprehensive handbook for developing a bladder cancer cystectomy database. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 812-826.	1.6	7
263	ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. European Urology, 2013, 63, 4-15.	1.9	225
264	Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center. European Urology, 2013, 64, 307-313.	1.9	147
265	Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2013, 190, 850-856.	0.4	101
266	1870 ALVIMOPAN, A PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONIST, ACCELERATES GASTROINTESTINAL RECOVERY AND DECREASES LENGTH OF HOSPITAL STAY AFTER RADICAL CYSTECTOMY. Journal of Urology, 2013, 189, .	0.4	4
267	Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1676-1682.	1.6	19
268	Genetic variations in regulator of Gâ€protein signaling (RGS) confer risk of bladder cancer. Cancer, 2013, 119, 1643-1651.	4.1	17
269	Strategies for Optimizing Bacillus Calmette-Guérin. Urologic Clinics of North America, 2013, 40, 211-218.	1.8	11
270	A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer. Cancer, 2013, 119, 540-547.	4.1	74

#	Article	IF	CITATIONS
271	Should histologic variants alter definitive treatment of bladder cancer?. Current Opinion in Urology, 2013, 23, 435-443.	1.8	42
272	A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin. Cancer Biology and Therapy, 2013, 14, 812-822.	3.4	18
273	Current clinical practice gaps in the treatment of intermediate―and highâ€risk nonâ€muscleâ€invasive bladder cancer (<scp>NMIBC</scp>) with emphasis on the use of bacillus <scp>C</scp> almetteâ€ <scp>G</scp> uérin (<scp>BCG</scp>): results of an international individual patient data survey (<scp>IPDS</scp>). BlU International. 2013. 112. 742-750.	2.5	87
274	Smac mimetic enables the anticancer action of BCC-stimulated neutrophils through TNF-α but not through TRAIL and FasL. Journal of Leukocyte Biology, 2012, 92, 233-244.	3.3	49
275	Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination. Oncolmmunology, 2012, 1, 1161-1162.	4.6	24
276	Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial. Journal of Urology, 2012, 187, 862-867.	0.4	78
277	The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 821-824.	1.6	33
278	Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: Summary of session at the Society of Urologic Oncology annual meeting. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 772-780.	1.6	33
279	Bladder Cancer and Upper Tracts. , 2012, , 311-333.		Ο
280	Imaging of Urothelial Cancers: What the Urologist Needs to Know. American Journal of Roentgenology, 2011, 196, 1249-1254.	2.2	19
281	Robot Assisted Extended Pelvic Lymphadenectomy at Radical Cystectomy: Lymph Node Yield Compared With Second Look Open Dissection. Journal of Urology, 2011, 185, 79-84.	0.4	55
282	Is Repeat Transurethral Resection Needed for Minimally Invasive T1 Urothelial Cancer?. Journal of Urology, 2011, 186, 788-789.	0.4	1
283	Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU International, 2011, 108, 1119-1123.	2.5	64
284	Fluorescence cystoscopy for nonmuscle invasive bladder cancer. Cancer, 2011, 117, 882-883.	4.1	5
285	Bladder cancer: imperatives for personalized medicine. Oncology, 2011, 25, 951-8, 960.	0.5	7
286	An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously) Tj ETQq(0 0 0 gBT	/Overlock 10
287	Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Cancer, 2010, 116, 340-346.	4.1	49

#	Article	IF	CITATIONS
289	Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial. Clinical Cancer Research, 2010, 16, 2861-2871.	7.0	404
290	Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non–Muscle-Invasive Bladder Cancer. Cancer Prevention Research, 2010, 3, 1235-1245.	1.5	45
291	Bladder Cancer Stem Cells. Current Stem Cell Research and Therapy, 2010, 5, 387-395.	1.3	33
292	Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biology and Therapy, 2010, 10, 885-892.	3.4	33
293	Perioperative Intravesical Therapy After Transurethral Resection for Bladder Cancer. Journal of Urology, 2010, 183, 19-20.	0.4	6
294	Definition and management of patients with bladder cancer who fail BCG therapy. Expert Review of Anticancer Therapy, 2009, 9, 815-820.	2.4	25
295	Curcumin Potentiates the Antitumor Effects of Bacillus Calmette-Guerin against Bladder Cancer through the Downregulation of NF-κB and Upregulation of TRAIL Receptors. Cancer Research, 2009, 69, 8958-8966.	0.9	95
296	Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer. Journal of Clinical Oncology, 2009, 27, 2592-2597.	1.6	148
297	Outcome of Patients With Bladder Cancer With pN+ Disease After Preoperative Chemotherapy and Radical Cystectomy. Urology, 2009, 73, 147-152.	1.0	63
298	Friend or foe? Role of peroxisome proliferator-activated receptor-Î ³ in human bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 585-591.	1.6	18
299	Editorial Comment. Journal of Urology, 2009, 182, 2630-2630.	0.4	0
300	Intravesical BCG for bladder cancer. Cancer, 2008, 113, 674-676.	4.1	2
301	Considerations on the use of diagnostic markers in management of patients with bladder cancer. World Journal of Urology, 2008, 26, 39-44.	2.2	21
302	1,1-Bis(3′-indolyl)-1-(<i>p</i> -chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Molecular Cancer Therapeutics, 2008, 7, 3825-3833.	4.1	95
303	Prostatic Urethral Biopsy Has Limited Usefulness in Counseling Patients Regarding Final Urethral Margin Status During Orthotopic Neobladder Reconstruction. Journal of Urology, 2008, 180, 164-167.	0.4	42
304	Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer. Indian Journal of Urology, 2008, 24, 77.	0.6	2
305	Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-κB and nuclear factor-κB–regulated gene products in IFN-̱–sensitive and IFN-ݱ–resistant human bladder cancer cells. Molecular Cancer Therapeutics, 2007, 6, 1022-1030.	4.1	152
306	Statins and the Effect of BCG on Bladder Cancer. New England Journal of Medicine, 2007, 356, 1276-1277.	27.0	25

#	Article	IF	CITATIONS
307	Ability of Clinical Grade to Predict Final Pathologic Stage in Upper Urinary Tract Transitional Cell Carcinoma: Implications for Therapy. Urology, 2007, 70, 252-256.	1.0	107
308	Lymph node density: surrogate marker for quality of resection in bladder cancer?. Expert Review of Anticancer Therapy, 2007, 7, 777-779.	2.4	5
309	Differences in Survival Among Patients With Sarcomatoid Carcinoma, Carcinosarcoma and Urothelial Carcinoma of the Bladder. Journal of Urology, 2007, 178, 2302-2307.	0.4	146
310	Micropapillary bladder cancer. Cancer, 2007, 110, 62-67.	4.1	253
311	Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder. Cancer, 2007, 110, 764-769.	4.1	84
312	PO Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. European Urology, 2007, 52, 769-776.	1.9	61
313	Treatment of bladder cancer in cardiac transplant patients. International Urology and Nephrology, 2007, 38, 477-479.	1.4	1
314	Controversial issues and optimal management of stage T1G3 bladder cancer. Expert Review of Anticancer Therapy, 2006, 6, 1283-1294.	2.4	10
315	Chemoprevention for Bladder Cancer. Journal of Urology, 2006, 176, 1914-1920.	0.4	33
316	The Case for Early Cystectomy in the Treatment of Nonmuscle Invasive Micropapillary Bladder Carcinoma. Journal of Urology, 2006, 175, 881-885.	0.4	194
317	Evaluation of the Relevance of Lymph Node Density in a Contemporary Series of Patients Undergoing Radical Cystectomy. Journal of Urology, 2006, 176, 53-57.	0.4	94
318	Contemporary Intravesical Treatment Options for Urothelial Carcinoma of the Bladder. Journal of the National Comprehensive Cancer Network: JNCCN, 2006, 4, 1027-1036.	4.9	20
319	Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer, 2006, 107, 1491-1495.	4.1	21
320	A combination of intravesical and BCG electromotive mitomycin for high-risk superficial bladder cancer. Nature Reviews Urology, 2006, 3, 472-473.	1.4	3
321	Inhibition of Bladder Tumor Growth by 1,1-Bis(3′-Indolyl)-1-(p-Substitutedphenyl)Methanes: A New Class of Peroxisome Proliferator-Activated Receptor γ Agonists. Cancer Research, 2006, 66, 412-418.	0.9	93
322	Atorvastatin: A potential chemopreventive agent in bladder cancer. Urology, 2005, 66, 1209-1212.	1.0	35
323	Metastatic penile cancer in a young Caucasian male: Impact of delayed diagnosis. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 130-131.	1.6	3
324	Diffuse granulomatous mesenteric disease caused by intravesical bacillus Calmette-Guérin instillation masquerading as peritoneal carcinomatosis. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 352-353.	1.6	2

#	Article	IF	CITATIONS
325	VALIDATION OF CRITERIA USED TO PREDICT EXTRAPROSTATIC CANCER EXTENSION: A TOOL FOR USE IN SELECTING PATIENTS FOR NERVE SPARING RADICAL PROSTATECTOMY. Journal of Urology, 2005, 174, 1262-1265.	0.4	24
326	Current state of immunotherapy for bladder cancer. Expert Review of Anticancer Therapy, 2004, 4, 1037-1046.	2.4	13
327	Focus on bladder cancer. Cancer Cell, 2004, 6, 111-116.	16.8	252
328	Metastatic Epithelioid Hemangioendothelioma of the Penis Managed With Surgery and Interferon-α. Journal of Urology, 2004, 171, 1886-1887.	0.4	9
329	Treatment of muscle-invasive bladder cancer: progress and new challenges. Expert Review of Anticancer Therapy, 2004, 4, 1047-1056.	2.4	11
330	Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology, 2004, 63, 46-50.	1.0	86
331	Antitumor activity of common antibiotics against superficial bladder cancer. Urology, 2004, 63, 457-460.	1.0	47
332	Rise in serum psa of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. Urology, 2004, 63, 1132-1137.	1.0	13
333	The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Molecular Cancer Therapeutics, 2004, 3, 279-90.	4.1	63
334	Identification of Factors Predicting Response to Adjuvant Radiation Therapy in Patients With Positive Margins After Radical Prostatectomy. Journal of Urology, 2003, 170, 1860-1863.	0.4	25
335	Total Pelvic Exenteration: Effective Palliation of Perineal Pain in Patients With Locally Recurrent Prostate Cancer. Journal of Urology, 2003, 170, 1868-1871.	0.4	59
336	Chemoprevention of superficial bladder cancer. Expert Review of Anticancer Therapy, 2003, 3, 799-808.	2.4	5
337	Chemoprevention of bladder cancer. Urologic Clinics of North America, 2002, 29, 157-168.	1.8	31
338	Immunotherapy for bladder cancer. Current Urology Reports, 2001, 2, 62-69.	2.2	35
339	Intravesical therapy for bladder cancer. Urology, 2000, 55, 161-168.	1.0	53
340	CHEMOPREVENTION OF UROLOGICAL CANCER. Journal of Urology, 1999, 161, 1748-1760.	0.4	62